Background
The Medicines Company was invited to submit evidence for this single technology appraisal for cangrelor in October 2014.
The company informed NICE that it would not be providing an evidence submission because there was insufficient data to develop the appropriate cost‑effectiveness assessment of cangrelor for the population covered in the marketing authorisation, that is, adult patients with coronary artery disease undergoing percutaneous coronary intervention who have not received an oral P2Y12 inhibitor prior to the PCI procedure and in whom oral therapy with P2Y12 inhibitors is not feasible or desirable.
NICE has therefore terminated this single technology appraisal.